Memphasys Limited announces Felix™ System outperforms DGC+SU method in Japanese clinical trial

Australian-based reproductive biotechnology company, Memphasys Limited (ASX: $MEM), has announced that its flagship Felix™ System has outperformed a sperm preparation method comprising two widely used technologies, a combination of Density Gradient Centrifugation followed by Swim-Up (DGC+SU), in findings from a recently completed Japanese clinical trial at the Reproduction Clinic Osaka, Japan.

Executive Commentary on Felix™ System's Performance

Dr Tomomoto Ishikawa, CEO and Owner of the Reproduction clinic Osaka, expressed excitement about the clinical performance of the Felix™ System, highlighting its ability to select high-quality sperm quickly and efficiently. Memphasys Managing Director and CEO (Acting) Dr David Ali emphasized the significant benefits of the Felix™ System over widely used methods, particularly in improving lab operations and workflow.

Summary of Felix™ System's Performance and Future Outlook

The Felix™ System has shown clear benefits over the DGC+SU method in the Japanese clinical trial, with improved clinical measures and a significantly shorter processing time. The upcoming presentation of trial findings at the ESHRE conference and the ongoing larger randomised double-blinded study at Monash IVF indicate a positive outlook for Memphasys. The company aims to further validate the system's performance and efficiency, potentially leading to increased adoption and commercial success.